Viltepso (Viltolarsen) Patent Expiration, LOE Window & CMS Spending

Viltepso (Viltolarsen) by Nippon Shinyaku: FDA Orange Book core substance LOE 2034-04-03, 0 AB generics, $69.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNippon Shinyaku
FDA Application & PathwayN212154 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-04-03
Last Listed Patent or Exclusivity Date2034-04-03
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$69.0M
2024 Medicare Part D Spend$4.3M
2024 Medicaid Spend$64.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel